Non-invasive quantification of 18F-florbetaben with total-body EXPLORER PET

Non-invasive quantification of 18F-florbetaben with total-body EXPLORER PET

Abstract Background Kinetic modeling of 18F-florbetaben provides important quantification of brain amyloid deposition in research and clinical settings but its use is limited by the requirement of arterial blood data for quantitative PET. The total-body EXPLORER PET scanner supports the dynamic acqu...

Full description

Bibliographic Details
Main Authors:	Emily Nicole Holy, Elizabeth Li, Anjan Bhattarai, Evan Fletcher, Evelyn R. Alfaro, Danielle J. Harvey, Benjamin A. Spencer, Simon R. Cherry, Charles S. DeCarli, Audrey P. Fan
Format:	Article
Language:	English
Published:	SpringerOpen 2024-04-01
Series:	EJNMMI Research
Subjects:	18F-florbetaben Alzheimer disease β-Amyloid Total body EXPLORER PET Kinetic modeling, image derived input function
Online Access:	https://doi.org/10.1186/s13550-024-01104-7

Similar Items

18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition
by: Lucia Baratto, et al.
Published: (2018-07-01)

Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases
by: Sonja Daerr, et al.
Published: (2017-01-01)

18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients
by: Yan Chang, et al.
Published: (2020-07-01)

Vision Transformer Approach for Classification of Alzheimer’s Disease Using 18F-Florbetaben Brain Images
by: Hyunji Shin, et al.
Published: (2023-03-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
by: Fiona Heeman, et al.
Published: (2019-03-01)

A simple and efficient automated microvolume radiosynthesis of [18F]Florbetaben
by: Ksenia Lisova, et al.
Published: (2020-12-01)

Automated spatial brain normalization and hindbrain white matter reference tissue give improved [18F]-florbetaben PET quantitation in Alzheimer´s model mice
by: Felix eOverhoff, et al.
Published: (2016-02-01)

Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer’s disease
by: Hai-Jeon Yoon, et al.
Published: (2021-01-01)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents 18F-flutemetamol and 18F-florbetaben
by: Hye Joo Son, et al.
Published: (2018-07-01)

In vivo Imaging With 18F-FDG- and 18F-Florbetaben-PET/MRI Detects Pathological Changes in the Brain of the Commonly Used 5XFAD Mouse Model of Alzheimer's Disease
by: Timon N. Franke, et al.
Published: (2020-09-01)

Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer’s Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography
by: Antje Willuweit, et al.
Published: (2021-10-01)

Generation of Conventional <sup>18</sup>F-FDG PET Images from <sup>18</sup>F-Florbetaben PET Images Using Generative Adversarial Network: A Preliminary Study Using ADNI Dataset
by: Hyung Jin Choi, et al.
Published: (2023-07-01)

High Correlation of Static First-Minute-Frame (FMF) PET Imaging after <sup>18</sup>F-Labeled Amyloid Tracer Injection with [<sup>18</sup>F]FDG PET Imaging
by: Alexander P. Seiffert, et al.
Published: (2021-07-01)

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
by: Alexander S. Mihaescu, et al.
Published: (2022-09-01)

A universal neocortical mask for Centiloid quantification
by: Pierrick Bourgeat, et al.
Published: (2023-07-01)

Classification of Alzheimer’s Disease Using Dual-Phase <sup>18</sup>F-Florbetaben Image with Rank-Based Feature Selection and Machine Learning
by: Hyun-Ji Shin, et al.
Published: (2022-07-01)

Automated Synthesis and Preliminary Clinical Application of 18F-Florbetabe
by: FU Huaping;ZHANG Xiaojun;CHANG Yan;WANG Yuan;ZHANG Jinming
Published: (2021-08-01)

Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study
by: Santiago Bullich, et al.
Published: (2022-07-01)

PET amyloid imaging: state of the art and technical considerations
by: Antonietta Arminio, et al.
Published: (2022-06-01)

Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels
by: Jaeho Kim, et al.
Published: (2023-03-01)

Severity of Subjective Cognitive Complaints and Worries in Older Adults Are Associated With Cerebral Amyloid-β Load
by: Claudia Schwarz, et al.
Published: (2021-08-01)

Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
by: Tracy R. Melzer, et al.
Published: (2019-04-01)

Classification of amyloid status using machine learning with histograms of oriented 3D gradients
by: Liam Cattell, et al.
Published: (2016-01-01)

A Case Report of Early-Onset Alzheimer’s Disease Using <sup>18</sup>F-FDG PET and <sup>18</sup>F-FBB PET
by: Jang Yoo, et al.
Published: (2023-05-01)

L’imaging dell’amiloide in PET: stato dell’arte e considerazioni tecniche
by: Antonietta Arminio, et al.
Published: (2022-06-01)

Patterns of Focal Amyloid Deposition Using <sup>18</sup>F-Florbetaben PET in Patients with Cognitive Impairment
by: Sung-eun Chung, et al.
Published: (2022-05-01)

Non-standard pipeline without MRI has replicability in computation of Centiloid scale values for PiB and 18F-labeled amyloid PET tracers
by: Motonobu Fujishima, et al.
Published: (2022-09-01)

Selective Serotonin Reuptake Inhibitor-Treatment Does Not Show Beneficial Effects on Cognition or Amyloid Burden in Cognitively Impaired and Cognitively Normal Subjects
by: Yvonne Bouter, et al.
Published: (2022-06-01)

Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative
by: Marta Marquié, et al.
Published: (2020-03-01)

Quantitative Brain Positron Emission Tomography in Female 5XFAD Alzheimer Mice: Pathological Features and Sex-Specific Alterations
by: Caroline Bouter, et al.
Published: (2021-11-01)

Alterations in Gut Microbiota and Their Correlation with Brain Beta-Amyloid Burden Measured by <sup>18</sup>F-Florbetaben PET in Mild Cognitive Impairment Due to Alzheimer’s Disease
by: Geon Ha Kim, et al.
Published: (2024-03-01)

Using CT Data to Improve the Quantitative Analysis of 18F-FBB PET Neuroimages
by: Fermín Segovia, et al.
Published: (2018-06-01)

Simple Quantification of Surface Uptake in F-18 Florapronol PET/CT Imaging for the Validation of Alzheimer’s Disease
by: Do-Hoon Kim, et al.
Published: (2022-01-01)

Clinical Relevance of [<sup>18</sup>F]Florbetaben and [<sup>18</sup>F]FDG PET/CT Imaging on the Management of Patients with Dementia
by: Damiano Librizzi, et al.
Published: (2021-02-01)

Optimizing quantification of MK6240 tau PET in unimpaired older adults
by: Theresa M. Harrison, et al.
Published: (2023-01-01)

Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories
by: Sarah F. Ackley, et al.
Published: (2021-01-01)

Development of software for measuring brain amyloid accumulation using 18F‐florbetapir PET and calculating global Centiloid scale and regional Z‐score values
by: Hiroshi Matsuda, et al.
Published: (2023-07-01)

<sup>18</sup>F–THK–5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer’s Disease: A Pictorial Insight into Disease Pathophysiology
by: Sohee Park, et al.
Published: (2021-04-01)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
by: Hugh G. Pemberton, et al.
Published: (2023-05-01)

Staging of amyloid β, t‐tau, regional atrophy rates, and cognitive change in a nondemented cohort: Results of serial mediation analyses
by: Evan Fletcher, et al.
Published: (2018-01-01)